A novel vaccine for mantle cell lymphoma based on targeting cyclin D1 to dendritic cells via CD40

[1] Foran JM(2000)Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response Ann Oncol 11 117-21

[2] Cunningham D(2010)Mantle cell lymphoma: report of the 2009 mantle cell lymphoma consortium workshop Leuk Lymphoma 51 390-8

[3] Coiffier B(2014)Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT) Ann Oncol 25 1053-8

[4] Solal-Celigny P(2006)Expression of the cyclin-dependent kinase inhibitor p27 and its deregulation in mouse B cell lymphomas Leuk Res 30 153-63

[5] Reyes F(2008)Advances in the understanding of mantle cell lymphoma Br J Haematol 142 149-65

[6] Ghielmini M(2013)CCND2 rearrangements are the most frequent genetic events in cyclin D1(−) mantle cell lymphoma Blood 121 1394-402

[7] Williams ME(2006)Mantle cell lymphoma in Taiwan: clinicopathological and molecular study of 21 cases including one cyclin D1-negative tumor expressing cyclin D2 Pathol Int 56 440-8

[8] Dreyling MH(2005)Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling Blood 106 4315-21

[9] Kahl BS(2013)Cyclin D1-negative mantle cell lymphoma Blood 121 1249-50

[10] Leonard JP(2003)Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation Blood 102 1588-94

[1] Foran JM(2000)Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response Ann Oncol 11 117-21

[2] Cunningham D(2010)Mantle cell lymphoma: report of the 2009 mantle cell lymphoma consortium workshop Leuk Lymphoma 51 390-8

[3] Coiffier B(2014)Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT) Ann Oncol 25 1053-8

[4] Solal-Celigny P(2006)Expression of the cyclin-dependent kinase inhibitor p27 and its deregulation in mouse B cell lymphomas Leuk Res 30 153-63

[5] Reyes F(2008)Advances in the understanding of mantle cell lymphoma Br J Haematol 142 149-65

[6] Ghielmini M(2013)CCND2 rearrangements are the most frequent genetic events in cyclin D1(−) mantle cell lymphoma Blood 121 1394-402

[7] Williams ME(2006)Mantle cell lymphoma in Taiwan: clinicopathological and molecular study of 21 cases including one cyclin D1-negative tumor expressing cyclin D2 Pathol Int 56 440-8

[8] Dreyling MH(2005)Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling Blood 106 4315-21

[9] Kahl BS(2013)Cyclin D1-negative mantle cell lymphoma Blood 121 1249-50

[10] Leonard JP(2003)Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation Blood 102 1588-94